Shanghai MicroPort MedBot Group Co Ltd
HKEX:2252
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
S
|
Shanghai MicroPort MedBot Group Co Ltd
HKEX:2252
|
29B HKD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
195.4B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
172.4B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
140B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
127.3B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
110.9B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
45.8B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
50.2B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
50.5B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.4B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
36.6B USD |
Loading...
|
Market Distribution
| Min | -416 945.9% |
| 30th Percentile | -1.5% |
| Median | 3.5% |
| 70th Percentile | 8.9% |
| Max | 17 382.1% |
Other Profitability Ratios
Shanghai MicroPort MedBot Group Co Ltd
Glance View
Shanghai MicroPort MedBot Group Co Ltd is a dynamic player in the medical innovation sector, strategically positioned at the crossroads of advanced technology and healthcare. Born out of a vision to revolutionize surgical practices, MedBot has dedicated itself to the development and commercialization of robotic-assisted systems. The company leverages cutting-edge research and development to create robotic platforms that aid surgeons in performing complex procedures with enhanced precision and control. Operating in a field where precision is paramount, MedBot's products are designed to minimize complications and reduce recovery times, catering to a global demand for improved surgical outcomes. MedBot generates its revenue by selling these sophisticated surgical robots to hospitals and healthcare institutions worldwide. Beyond the initial sale, the company benefits from offering ongoing service contracts, training, and support to ensure seamless integration and optimal performance of their products. Additionally, it capitalizes on the sale of consumables and replacement parts required for the long-term operation of their systems. Through its commitment to innovation and focus on addressing the complexities of surgical procedures, Shanghai MicroPort MedBot Group has carved out a distinctive niche, continually expanding its influence within the expanding scope of minimally invasive surgery.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Shanghai MicroPort MedBot Group Co Ltd is -143.4%, which is above its 3-year median of -726.2%.
Over the last 3 years, Shanghai MicroPort MedBot Group Co Ltd’s Net Margin has increased from -25 015.9% to -143.4%. During this period, it reached a low of -25 015.9% on Jun 30, 2022 and a high of -143.4% on Jun 30, 2025.